22.05.2015 - Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.
Ballerup-based LEO Pharma will get access to one of arGEN-X’ antibodies, which is currently being developed for inflammation-related skin diseases. In return, arGEN-X will receive pre-IND payments of €4.5m, including an upfront payment, as well as milestone payments of up to €100m plus royalties. The allies will co-fund product development costs up to clinical trial application filing.
Breda-based arGEN-X N.V. develops therapeutic antibodies, and usually focuses on the treatment of cancer and severe autoimmune diseases. Danish LEO Pharma A/S, on the other hand, specialises in skin-related therapies, such as treatments for psoriasis and actinic keratosis. “We see huge potential in this new partnership in harnessing the complementary expertise of both companies: arGEN-X’ advanced knowledge and capabilities in therapeutic antibody development and LEO Pharma’s global expertise in bringing products to market that meet the needs of dermatology patients,” said Tim Van Hauwermeiren, Chief Executive Officer of arGEN-X. Added Thorsten Thormann, Senior Vice President, New Product Discovery at LEO Pharma: “Our alliance with arGEN-X is an important step forward as it marks our entry into the area of biotherapeutics for dermatology.”
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs. more